QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company develop...

 ubs-maintains-buy-on-alx-oncology-holdings-lowers-price-target-to-4

UBS analyst Colin Bristow maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and lowers the price target from $25 to $4.

 hc-wainwright--co-reiterates-buy-on-alx-oncology-holdings-maintains-25-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and maintai...

 cantor-fitzgerald-reiterates-overweight-on-alx-oncology-holdings

Cantor Fitzgerald analyst Li Watsek reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Overweight.

 stifel-reiterates-hold-on-alx-oncology-holdings-lowers-price-target-to-3

Stifel analyst Bradley Canino reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Hold and lowers the price target from $5...

 alx-oncology-holdings-q2-eps-076-beats-077-estimate

ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of...

 stifel-maintains-hold-on-alx-oncology-holdings-lowers-price-target-to-5

Stifel analyst Bradley Canino maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Hold and lowers the price target from $14...

 immuno-oncology-focused-alx-oncology-stock-falls-on-updated-data-from-mid-stage-evorpacept-combo-study-in-gastric-cancer-patients

ALX Oncology announces Phase 2 ASPEN-06 trial results for evorpacept in combination with trastuzumab, Cyramza, and paclitaxel f...

 hc-wainwright--co-reiterates-buy-on-alx-oncology-holdings-maintains-25-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and maintai...

Core News & Articles
Market-Moving News for August 1st
08/01/2024 12:21:36

META: 8% | Meta shares are trading higher after the company reported better-than-expected Q2 financial results and issued Q3 gu...

 alx-oncology-reports-data-from-aspen-06-phase-2-trial-says-evorpacept-combination-achieved-confirmed-overall-response-rate-of-403-compared-to-266-for-control-arm

Evorpacept is the first CD47 blocker to show durable clinical benefit and a well-tolerated safety profile in a prospective rand...

 alx-oncology-to-announce-phase-2-trial-results-for-her2-positive-gastric-cancer-at-430-pm-edt

ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), an immuno-oncology company develop...

 hc-wainwright--co-reiterates-buy-on-alx-oncology-holdings-maintains-25-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and maintai...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION